Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDITNASDAQ:FMTXNASDAQ:PCVXNASDAQ:SRRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$1.13-2.6%$1.51$1.12▼$7.13$93.76M1.882.55 million shs2.12 million shsFMTXForma Therapeutics$20.01$20.00$4.95▼$20.68$957.54M-0.94847,595 shs1 shsPCVXVaxcyte$32.23-14.6%$78.00$30.12▼$121.06$4.15B1.021.07 million shs8.89 million shsSRRKScholar Rock$30.06-6.5%$37.22$6.76▼$46.98$2.85B0.591.18 million shs2.15 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine-2.59%-13.08%-41.15%-11.02%-84.48%FMTXForma Therapeutics0.00%0.00%0.00%0.00%0.00%PCVXVaxcyte-14.65%-55.17%-55.86%-60.63%-51.70%SRRKScholar Rock-6.50%-9.68%-22.57%-30.45%+79.04%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDITEditas Medicine4.1842 of 5 stars3.03.00.04.32.81.71.3FMTXForma TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APCVXVaxcyte2.023 of 5 stars3.50.00.00.03.92.50.0SRRKScholar Rock4.0962 of 5 stars3.50.00.04.43.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.07Hold$6.83504.72% UpsideFMTXForma Therapeutics 0.00N/AN/AN/APCVXVaxcyte 3.00Buy$136.50323.52% UpsideSRRKScholar Rock 3.00Buy$42.6741.94% UpsideCurrent Analyst Ratings BreakdownLatest PCVX, FMTX, SRRK, and EDIT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$138.00 ➝ $100.004/1/2025PCVXVaxcyteBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$157.00 ➝ $137.004/1/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $90.003/25/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/17/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.003/12/2025PCVXVaxcyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$160.00 ➝ $160.002/26/2025PCVXVaxcyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$160.00 ➝ $160.002/26/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $140.002/11/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.001/29/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$47.001/9/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$47.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$32.31M2.90N/AN/A$4.27 per share0.26FMTXForma Therapeutics$100.56M9.52N/AN/A$10.51 per share1.90PCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/ASRRKScholar Rock$33.19M85.75N/AN/A$3.12 per share9.63Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$153.22M-$2.88N/AN/AN/A-340.96%-80.13%-50.99%5/6/2025 (Estimated)FMTXForma Therapeutics-$172.96M-$4.00N/AN/AN/AN/A-39.68%-35.33%N/APCVXVaxcyte-$402.27M-$3.80N/AN/AN/AN/A-23.53%-22.20%5/6/2025 (Estimated)SRRKScholar Rock-$165.79M-$2.45N/AN/AN/AN/A-145.60%-91.83%5/6/2025 (Estimated)Latest PCVX, FMTX, SRRK, and EDIT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/5/2025Q4 2024EDITEditas Medicine-$0.39-$0.55-$0.16-$0.55$37.17 million$30.60 million2/25/2025Q4 2024PCVXVaxcyte-$1.16-$1.02+$0.14-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AFMTXForma TherapeuticsN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.753.75FMTXForma TherapeuticsN/A12.7412.74PCVXVaxcyteN/A17.8817.88SRRKScholar Rock0.633.883.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%FMTXForma Therapeutics87.39%PCVXVaxcyte96.78%SRRKScholar Rock91.08%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%FMTXForma Therapeutics5.79%PCVXVaxcyte3.10%SRRKScholar Rock19.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23082.98 million80.98 millionOptionableFMTXForma Therapeutics16647.85 million45.08 millionNot OptionablePCVXVaxcyte160128.76 million120.77 millionOptionableSRRKScholar Rock14094.68 million75.64 millionOptionablePCVX, FMTX, SRRK, and EDIT HeadlinesRecent News About These CompaniesCorient Private Wealth LLC Takes $394,000 Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 31 at 3:18 AM | marketbeat.comAmerican Century Companies Inc. Acquires New Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)March 30 at 3:45 AM | marketbeat.comRaymond James Financial Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 30 at 3:15 AM | marketbeat.comLoomis Sayles & Co. L P Makes New Investment in Scholar Rock Holding Co. (NASDAQ:SRRK)March 29, 2025 | marketbeat.comBIT Capital GmbH Decreases Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 28, 2025 | marketbeat.comScholar Rock Announces FDA Priority Review Designation For Apitegromab - Quick FactsMarch 27, 2025 | nasdaq.comFDA accepts Scholar Rock BLA for apitegromab under priority review to treat SMAMarch 27, 2025 | markets.businessinsider.comInsider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells 6,500 Shares of StockMarch 26, 2025 | marketbeat.comScholar Rock (NASDAQ:SRRK) Receives "Outperform" Rating from WedbushMarch 26, 2025 | marketbeat.comSwiss National Bank Boosts Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 25, 2025 | marketbeat.comVictory Capital Management Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)March 23, 2025 | marketbeat.comAlphaQuest LLC Sells 34,414 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)March 21, 2025 | marketbeat.comScholar Rock Holding Co. (NASDAQ:SRRK) Director Katie Peng Sells 1,006 SharesMarch 20, 2025 | marketbeat.com54,717 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Bought by Proficio Capital Partners LLCMarch 19, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Scholar Rock (NASDAQ:SRRK)March 18, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Buys Shares of 28,599 Scholar Rock Holding Co. (NASDAQ:SRRK)March 18, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 119,616 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)March 18, 2025 | marketbeat.comTD Cowen Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)March 17, 2025 | markets.businessinsider.comScholar Rock announces Phase 3 SAPPHIRE dataMarch 16, 2025 | markets.businessinsider.comScholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific ConferenceMarch 16, 2025 | businesswire.comScholar Rock issues equity awards to new employeesMarch 16, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCVX, FMTX, SRRK, and EDIT Company DescriptionsEditas Medicine NASDAQ:EDIT$1.13 -0.03 (-2.59%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$1.14 +0.02 (+1.33%) As of 04/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Forma Therapeutics NASDAQ:FMTXForma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.Vaxcyte NASDAQ:PCVX$32.23 -5.53 (-14.65%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$32.70 +0.47 (+1.46%) As of 04/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Scholar Rock NASDAQ:SRRK$30.06 -2.09 (-6.50%) Closing price 04/1/2025 04:00 PM EasternExtended Trading$31.72 +1.66 (+5.52%) As of 04/1/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
